Why the study?
Following the SYMPLICITY HTN-3 trial and subsequent guideline demotions, the role of renal denervation in resistant hypertension is being re-evaluated in light of recently published trials.
Does radiofrequency renal artery denervation improve outcomes in patients with resistant hypertension?
Does radiofrequency renal artery denervation improve outcomes in patients with resistant hypertension?
The review discusses the evolving role and recent trial evidence of radiofrequency renal artery denervation in treating resistant hypertension.
Renal denervation role in resistant hypertension remains uncertain; leaves open need for definitive randomized outcome trials.
Radiofrequency renal artery denervation (RND) was introduced as a method of interventional treatment of resistant hypertension almost ten years ago. The first studies demonstrated the effectiveness of this procedure. This has led to growing interest in this area and the rapid development of the method. However, the results of the first randomized trial of SYMPLICITY HTN-3 questioned the role of RND in the treatment of resistant hypertension, this fact conducted to the decrease in the recommendation class and level of evidence in the Guidelines of the European Society of Cardiology and the European Society of Hypertension in 2018. To date, the medical community is actively discussing the results of recently published trials such as SPYRAL HTN-OFF MED, SPYRAL HTN-ON MED, RADIANCE-HTN SOLO and RADIOSOUND-HTN.
No takes yet. Share an insight, caveat, or question.
Agaeva et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: